Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-17 · accession 0001415889-24-013630 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-17 | 2024-05-17 | JBIO | Gillies Hunter | Chief MEDICAL Off | S - Sale+OE | $21.09 | -4,000 | 5,688 | -41% | -$84.3K |
| D | 2024-05-17 | 2024-05-17 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $2.14 | +4,000 | 9,602 | +71% | +$8,560 |
| D | 2024-05-17 | 2024-05-17 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $0.00 | -4,000 | 11.3K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-17 | S | D | 86 | $21.86 | 5,602 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-17 | S | D | 3,914 | $21.07 | 5,688 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.605 to $21.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2024-05-17 | M | A | 4,000 | $2.14 | 9,602 | D | — | — | (F2) Includes 2,351 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d). |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-05-17 | M | D | 4,000 | $0.00 | 11,324 | D | $2.14 · — to 2031-04-01 | 4,000 Common Stock | (F4) A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. |